2016 brought with it the first fall in deaths from hepatitis C in the UK in more than a decade, likely the result of increased treatment with new direct acting antiviral drugs
Straightforward change to anachronistic law that criminalised honest errors has taken a decade.
In October, twelve NHS clinical commissioning groups across northeast England and Cumbria agreed a policy to offer patients in the region with wet (neovascular) age-related macular degeneration the choice of ‘off-label’ use of bevacizumab (Avastin) as preferred treatment, with potential savings of up to £13.5m over the next five years.
Avoiding medicines stalemate post BrexitSubscription
With three rounds of negotiations concluded and little agreed, the reality of a no-deal Brexit looms large over both the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA).
Recent reports that GPs have resorted to underhand tactics to try to encourage patients not to go to a pharmacist for their annual flu vaccination are disturbing, but perhaps not all that surprising.
Pharmacists are well placed to manage the complex medication regimens of patients with Parkinson’s disease by not only addressing a raft of motor and non-motor symptoms but also managing other co-morbidities, such as diabetes or hypertension.
AMR: time is running out, we need action nowSubscription
AMR is one of the biggest threats to modern medicine and the global economy, yet millions of people are unaware of its potentially catastrophic implications.
Community pharmacists, working collaboratively with other healthcare professionals, can care for patients with foot conditions, providing relief to a health system under strain. Produced in partnership with RB.
The new medicine service: evidence that community pharmacists are looking after patients while saving NHS resourcesSubscription
The latest research which shows the new medicine service is cost-effective is just what community pharmacy needs in these challenging times.
It is time for England to follow the lead of Wales, Scotland and Northern Ireland and abolish prescription charges.
Several clinical trials have been stopped because of safety concerns, but pharmaceutical companies should not lose their nerve.